<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 9.4: Macrovascular Disease: The Atherosclerosis-Insulin Link</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - DEEP BLUE/RED theme for Cardiovascular */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #2d3748;
            margin: 35px 0 15px 0;
            font-weight: 600;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #1e3a8a 0%, #1e40af 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
            color: white;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
            border: 1px solid #e5e7eb;
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        /* Tables */
        .data-table-container {
            overflow-x: auto;
            margin: 30px 0;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        .data-table th {
            background: #f1f5f9;
            padding: 15px;
            color: #1e3a8a;
            font-weight: 600;
            border-bottom: 2px solid #e2e8f0;
        }

        .data-table td {
            padding: 15px;
            border-bottom: 1px solid #e2e8f0;
            color: #475569;
        }

        .data-table tr:last-child td {
            border-bottom: none;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            transition: background 0.2s ease;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #1e40af;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #eff6ff;
            border-radius: 8px;
        }

        /* Key Takeaways */
        .takeaways-box {
            background: linear-gradient(135deg, #f1f5f9 0%, #e2e8f0 100%);
            padding: 25px;
            margin-top: 35px;
            border-radius: 12px;
            border: 1px solid #cbd5e1;
        }

        /* References Box */
        .references-box {
            margin-top: 50px;
            padding: 30px;
            background: #f8fafc;
            border-radius: 12px;
            border: 1px solid #e2e8f0;
        }

        .references-box h4 {
            margin: 0 0 15px 0;
            font-size: 14px;
            text-transform: uppercase;
            letter-spacing: 1px;
            color: #64748b;
        }

        .ref-list {
            list-style: none;
            padding: 0;
            margin: 0;
            font-size: 13px;
            color: #64748b;
            line-height: 1.6;
        }

        .ref-list li {
            margin-bottom: 10px;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 9: Advanced Pathophysiology & Metabolic Complications</p>
            <h1 class="lesson-title">Lesson 9.4: Macrovascular Disease: The Atherosclerosis-Insulin Link</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Lesson 4 of 4</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Endothelial Frontier</a></li>
                <li><a href="#section2"><span class="section-num">2</span>The Atherogenic Triad</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Insulin: The Pro-Atherogenic Signaling</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Inflammation & Plaque Stability</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Case Study: The "Normal" Lipid Panel Paradox</a></li>
                <li><a href="#section6"><span class="section-num">6</span>S.T.A.B.L.E. ASCVD Risk Reduction</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Analyze the mechanism of endothelial dysfunction as the primary driver of cardiovascular risk.</li>
                <li>Identify the components of 'Atherogenic Dyslipidemia' and why they are more predictive than LDL-C alone.</li>
                <li>Understand the bifurcated signaling of insulin in vascular cells and how resistance promotes plaque.</li>
                <li>Evaluate the role of chronic low-grade inflammation (hs-CRP) in coronary artery disease.</li>
                <li>Apply the S.T.A.B.L.E. Methodâ„¢ to improve 10-year ASCVD risk scores through lifestyle interventions.</li>
            </ul>
        </div>

        <p>While previous lessons in this module focused on the <span class="highlight">microvascular</span> damageâ€”the destruction of tiny capillaries in the eyes and kidneysâ€”this lesson pivots to the "silent killers": the large arteries. Macrovascular disease, including Coronary Artery Disease (CAD), Stroke, and Peripheral Artery Disease (PAD), is responsible for approximately 80% of all diabetes-related mortality.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">2-4x</div>
                    <div class="stat-label">Higher Risk of CVD</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">75%</div>
                    <div class="stat-label">CVD Mortality in T2D</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">10yr</div>
                    <div class="stat-label">Earlier Disease Onset</div>
                </div>
            </div>
        </div>

        <h2 id="section1">1. The Endothelial Frontier: Where Disease Begins</h2>
        <p>The <span class="highlight">endothelium</span> is a single layer of cells lining the entire vascular system. Far from being a simple barrier, it is a dynamic endocrine organ that regulates blood flow, prevents platelet aggregation, and controls inflammation. In the context of insulin resistance, the endothelium is the first casualty.</p>

        <p>The primary molecule of endothelial health is <span class="highlight">Nitric Oxide (NO)</span>. NO is a potent vasodilator that keeps blood vessels "slippery," preventing white blood cells and cholesterol from sticking to the walls. In a healthy state, insulin binds to endothelial cells and stimulates the production of NO via the PI3-kinase pathway. However, in the insulin-resistant state, this pathway is impaired.</p>

        <p>This leads to a state of constant vasoconstriction and "stickiness," known as <strong>Endothelial Dysfunction</strong>. Without adequate NO, the vessel walls become permeable, allowing LDL particles to enter the sub-endothelial space, where they become oxidizedâ€”the first step in plaque formation.</p>

        <h2 id="section2">2. The Atherogenic Dyslipidemia Triad</h2>
        <p>Standard lipid panels often fail to capture the true cardiovascular risk in diabetic clients. A client may present with "normal" LDL-C (LDL cholesterol) but still be at high risk for a myocardial infarction. This is due to the <span class="highlight">Atherogenic Triad</span>, a specific lipid pattern driven by insulin resistance.</p>

        <div class="data-table-container">
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Marker</th>
                        <th>The Triad Pattern</th>
                        <th>The Pathophysiological Impact</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Triglycerides (TG)</strong></td>
                        <td>Elevated (>150 mg/dL)</td>
                        <td>Increased VLDL production; drives the rest of the triad.</td>
                    </tr>
                    <tr>
                        <td><strong>HDL Cholesterol</strong></td>
                        <td>Low (<40 mg/dL m, <50 mg/dL f)</td>
                        <td>Reduced "reverse cholesterol transport" and anti-oxidative capacity.</td>
                    </tr>
                    <tr>
                        <td><strong>LDL Particle Size</strong></td>
                        <td>Small, Dense (Pattern B)</td>
                        <td>Easily oxidized; stays in circulation longer; highly pro-atherogenic.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <p>The most critical component here is the <span class="highlight">small-dense LDL (sdLDL)</span>. Unlike large, buoyant LDL particles, sdLDL can easily penetrate the arterial wall and is much more susceptible to glycation (linked to Lesson 9.2: AGEs). A 2021 study found that sdLDL concentration was a better predictor of cardiovascular events than total LDL-C in patients with metabolic syndrome.</p>

        <h2 id="section3">3. Insulin: The Pro-Atherogenic Signaling Paradox</h2>
        <p>A common misconception is that insulin resistance means the body stops responding to insulin entirely. In reality, insulin resistance is <strong>pathway-specific</strong>. In vascular smooth muscle cells, insulin signals through two primary pathways:</p>
        
        <ul class="content-list">
            <li><strong>The PI3-Kinase Pathway:</strong> Responsible for NO production (Vasodilation). This pathway becomes <em>resistant</em>.</li>
            <li><strong>The MAP-Kinase Pathway:</strong> Responsible for cell growth and migration (Vasoconstriction and Plaque thickening). This pathway remains <em>sensitive</em>.</li>
        </ul>

        <p>This creates a "perfect storm." While the body struggles to dilate vessels (low NO), the high levels of circulating insulin (hyperinsulinemia) continue to stimulate the MAP-kinase pathway, causing the arterial walls to thicken and stiffen. This <span class="highlight">vascular remodeling</span> significantly narrows the lumen of the artery, increasing blood pressure and the risk of blockage.</p>

        <h2 id="section4">4. Inflammation & Plaque Stability</h2>
        <p>Atherosclerosis is now recognized as a chronic inflammatory disease. In the diabetic environment, the presence of <span class="highlight">high-sensitivity C-Reactive Protein (hs-CRP)</span> is a hallmark of "vulnerable" plaque. Plaque stability is often more important than the size of the plaque itself.</p>

        <p>When the sub-endothelial space is filled with oxidized LDL and AGEs, macrophages (immune cells) arrive to clean up the mess. They "eat" the oxidized LDL and become <strong>foam cells</strong>. These foam cells release pro-inflammatory cytokines, which weaken the "fibrous cap" covering the plaque. If this cap ruptures, a clot forms instantly, leading to a heart attack or stroke.</p>

        <div class="alert-box info">
            <p class="alert-label">Practitioner Tip</p>
            <p>Monitor hs-CRP in your clients. A level >3.0 mg/L indicates high systemic inflammation and an increased risk of plaque rupture, even if glucose is relatively controlled.</p>
        </div>

        <h2 id="section5">5. Case Study: The "Normal" Lipid Panel Paradox</h2>
        
        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: David R.</p>
                    <p style="color: white; margin: 0; font-size: 13px;">Age: 54 | Condition: T2D & Hypertension</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">DR</div>
                    <div class="patient-info">
                        <h4>David R.</h4>
                        <p>LDL-C: 105 mg/dL (Normal) | TG: 240 mg/dL | HDL: 32 mg/dL</p>
                    </div>
                </div>
                <p><strong>Presentation:</strong> David was told by his GP that his cholesterol was "fine" because his LDL was near the target. However, he complained of shortness of breath during light walks and had a Fasting Insulin of 28 Î¼IU/mL (Severe IR).</p>
                <p><strong>Intervention (S.T.A.B.L.E. Method):</strong>
                    <ul>
                        <li><strong>Transform Nutrition:</strong> Focused on the TG/HDL ratio by eliminating processed fructose and increasing Omega-3 intake (EPA/DHA).</li>
                        <li><strong>Activate Movement:</strong> Zone 2 aerobic training to improve endothelial NO production.</li>
                        <li><strong>Balance Hormones:</strong> Targeted hyperinsulinemia reduction through intermittent fasting.</li>
                    </ul>
                </p>
                <p><strong>Outcomes:</strong> After 6 months, David's TG dropped to 110 mg/dL, and his HDL rose to 46 mg/dL. His TG/HDL ratio improved from 7.5 to 2.3. An advanced lipid test showed a shift from Pattern B (small-dense) to Pattern A (large-buoyant) LDL particles. His cardiovascular symptoms resolved.</p>
            </div>
        </div>

        <h2 id="section6">6. S.T.A.B.L.E. ASCVD Risk Reduction</h2>
        <p>As a Blood Sugar Coach, your goal is to reduce the 10-year <span class="highlight">Atherosclerotic Cardiovascular Disease (ASCVD)</span> risk score. We do this by addressing the root metabolic drivers rather than just the symptoms.</p>

        <div class="principle-card">
            <p class="principle-title">S: Screen & Assess</p>
            <p class="principle-text">Look beyond LDL. Calculate the TG/HDL ratio (Goal: < 2.0) and monitor hs-CRP. These are better proxies for insulin-driven macrovascular risk.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">T: Transform Nutrition</p>
            <p class="principle-text">Prioritize the "Fiber Matrix" (Lesson 2.4). Soluble fiber binds to bile acids, forcing the liver to use up LDL cholesterol to make more, effectively lowering sdLDL levels naturally.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">A: Activate Movement</p>
            <p class="principle-text">Shear stress from exercise is the most potent stimulator of NO. Resistance training specifically reduces the "stiffness" of macrovascular walls by improving insulin sensitivity in smooth muscle cells.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">L: Lifestyle Reset</p>
            <p class="principle-text">Sleep deprivation (Lesson 5.2) increases sympathetic nervous system activity, which causes vasoconstriction and exacerbates endothelial dysfunction. Aim for 7-9 hours to allow for vascular repair.</p>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of macrovascular pathophysiology.</p>
            
            <div class="question-item">
                <p class="question-text">1. Why is insulin resistance considered a "bifurcated" signaling problem in the arteries?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Because the pathway for Nitric Oxide (PI3-K) becomes resistant (leading to vasoconstriction), while the pathway for cell growth (MAPK) remains sensitive (leading to arterial thickening).</div>
            </div>

            <div class="question-item">
                <p class="question-text">2. Which lipid marker is the most significant component of the Atherogenic Triad in predicting plaque formation?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Small, dense LDL (sdLDL). These particles are smaller, stay in the blood longer, and are more easily oxidized and glycated compared to large LDL particles.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>Macrovascular disease is the leading cause of death in diabetic clients, driven primarily by insulin resistance.</li>
                <li>Endothelial dysfunction (loss of Nitric Oxide) is the earliest detectable stage of atherosclerosis.</li>
                <li>The TG/HDL ratio is a more powerful predictor of cardiovascular risk than total LDL-C in metabolic patients.</li>
                <li>Hyperinsulinemia directly promotes arterial wall thickening through the MAP-kinase pathway.</li>
                <li>Comprehensive risk reduction requires the S.T.A.B.L.E. Methodâ„¢ to address inflammation, lipids, and vascular tone simultaneously.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul class="ref-list">
                <li>Glovaci, D., et al. (2019). "Epidemiology of Diabetes Mellitus and Cardiovascular Disease." <i>Current Cardiology Reports</i>.</li>
                <li>Bornfeldt, K. E., & Tabas, I. (2011). "Insulin Resistance, Hyperglycemia, and Atherosclerosis." <i>Cell Metabolism</i>.</li>
                <li>Ormazabal, V., et al. (2018). "Association between insulin resistance and the development of cardiovascular disease." <i>Cardiovascular Diabetology</i>.</li>
                <li>Zhu, Y., et al. (2021). "Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk." <i>Journal of the American Heart Association</i>.</li>
                <li>King, G. L., et al. (2016). "Insulin resistance and endothelial dysfunction." <i>Current Opinion in Endocrinology, Diabetes and Obesity</i>.</li>
                <li>Libby, P. (2021). "The changing landscape of atherosclerosis." <i>Nature</i>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Diabetes & Blood Sugar Coach</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All rights reserved. The S.T.A.B.L.E. Methodâ„¢ is a proprietary framework.</p>
        </footer>
    </div>
</body>

</html>